Chase Doyle

Ibrutinib has showed clinically meaningful and durable responses in patients with chronic graph-versus-host-disease (cGVHD).

A second round of chemotherapy or stem cell transplant for patients with multiple myeloma does not improve PFS or OS compared to the current standard couse of treatment.